title: Anti-biofilm efficacy of a lactoferrin/xylitol wound hydrogel used in combination with silver wound dressings.
abstract: With an epidemic increase in obesity combined with an ageing population, chronic wounds such as diabetic foot ulcers, pressure ulcers and venous leg ulcers are an increasing clinical concern. Recent studies have shown that bacterial biofilms are a major contributor to wound bioburden and interfere with the normal wound healing process; therefore, rational design of wound therapies should include analysis of anti-biofilm characteristics. Studies using the combined treatment of bacterial biofilms with the innate immune molecule lactoferrin and the rare sugar-alcohol xylitol have demonstrated an antimicrobial capacity against a clinical wound isolate. Studies presented here used a colony-drip-flow reactor biofilm model to assess the anti-biofilm efficacy of a lactoferrin/xylitol hydrogel used in combination with commercially available silver-based wound dressings. Log reductions in biofilm viability are compared with a commercially available wound hydrogel used in combination with the silver-based wound dressings. For both a single species biofilm and a dual species biofilm, the lactoferrin/xylitol hydrogel in combination with the silver wound dressing Acticoat™ had a statistically significant reduction in biofilm viability relative to the commercially available wound hydrogel. This study also demonstrated a statistical interaction between the lactoferrin/xylitol hydrogel and the silver wound dressing.
authors: Center for Biofilm Engineering, 366 EPS Building, Montana State University, 503 N. Bozeman Ave, Bozeman, MT, USA. mcammons@gmail.com
authors: Mary Cloud B
authors: MC
authors: Ammons
authors: Loren S
authors: LS
authors: Ward
authors: Garth A
authors: GA
authors: James
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology; D047070:Bandages, Hydrocolloid; D018441:Biofilms / Q000187:drug effects*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D007781:Lactoferrin / Q000494:pharmacology*; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000502:physiology; D050296:Microbial Viability; D011550:Pseudomonas aeruginosa / Q000187:drug effects* / Q000502:physiology; D012680:Sensitivity and Specificity; D018030:Silver Compounds / Q000494:pharmacology*; D014946:Wound Infection / Q000628:therapy; D014993:Xylitol / Q000494:pharmacology*
chemical_list: D000900:Anti-Bacterial Agents; D018030:Silver Compounds; D007781:Lactoferrin; D014993:Xylitol